MLL-Rearranged Acute Leukemia with t(4;11)(q21;q23)—Current Treatment Options. Is There a Role for CAR-T Cell Therapy?
The MLL (mixed-lineage leukemia) gene, located on chromosome 11q23, is involved in
chromosomal translocations in a subtype of acute leukemia, which represents approximately …
chromosomal translocations in a subtype of acute leukemia, which represents approximately …
Multiparametric flow cytometry for MRD monitoring in hematologic malignancies: clinical applications and new challenges
G Riva, V Nasillo, AM Ottomano, G Bergonzini… - Cancers, 2021 - mdpi.com
Simple Summary In hematologic cancers, Minimal Residual Disease (MRD) monitoring,
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …
using either molecular (PCR) or immunophenotypic (MFC) diagnostics, allows the …
Single-cell analysis of target antigens of CAR-T reveals a potential landscape of “on-target, off-tumor toxicity”
Y Zhang, Y Li, W Cao, F Wang, X Xie, Y Li… - Frontiers in …, 2021 - frontiersin.org
Cellular immunotherapy represented by CD19-directed chimeric antigen receptor T (CAR-T)
cells has achieved great success in recent years. An increasing number of CAR-T therapies …
cells has achieved great success in recent years. An increasing number of CAR-T therapies …
Recent advances in targeted protein degraders as potential therapeutic agents
N Yang, B Kong, Z Zhu, F Huang, L Zhang, T Lu… - Molecular …, 2024 - Springer
Targeted protein degradation (TPD) technology has gradually become widespread in the
past 20 years, which greatly boosts the development of disease treatment. Contrary to small …
past 20 years, which greatly boosts the development of disease treatment. Contrary to small …
H3K79me2/3 controls enhancer–promoter interactions and activation of the pan-cancer stem cell marker PROM1/CD133 in MLL-AF4 leukemia cells
MLL gene rearrangements (MLLr) are a common cause of aggressive, incurable acute
lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The …
lymphoblastic leukemias (ALL) in infants and children, most of which originate in utero. The …
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
S Adnan Awad, O Dufva, A Ianevski, B Ghimire, J Koski… - Leukemia, 2021 - nature.com
Blast-phase chronic myeloid leukemia (BP-CML) is associated with additional chromosomal
aberrations, RUNX1 mutations being one of the most common. Tyrosine kinase inhibitor …
aberrations, RUNX1 mutations being one of the most common. Tyrosine kinase inhibitor …
[HTML][HTML] Inhibitory CARs fail to protect from immediate T cell cytotoxicity
MA Funk, G Heller, P Waidhofer-Söllner, J Leitner… - Molecular Therapy, 2024 - cell.com
Chimeric antigen receptors (CARs) equipped with an inhibitory signaling domain (iCARs)
have been proposed as strategy to increase on-tumor specificity of CAR-T cell therapies …
have been proposed as strategy to increase on-tumor specificity of CAR-T cell therapies …
[HTML][HTML] Histone–lysine N-methyltransferase 2 (KMT2) complexes–a new perspective
E Poreba, K Lesniewicz, J Durzynska - Mutation Research/Reviews in …, 2022 - Elsevier
Abstract Histone H3 Lys4 (H3K4) methylation is catalyzed by the Histone–Lysine N-
Methyltransferase 2 (KMT2) protein family, and its members are required for gene …
Methyltransferase 2 (KMT2) protein family, and its members are required for gene …
Efficacy, safety, and challenges of CAR T-cells in the treatment of solid tumors
Simple Summary Chimeric antigen receptor T cells (CAR T-cells) are engineered T cells that
target tumor-associated antigens. CAR T-cell therapy is a novel developed immunotherapy …
target tumor-associated antigens. CAR T-cell therapy is a novel developed immunotherapy …
Identification of targets to redirect CAR T cells in glioblastoma and colorectal cancer: an arduous venture
E Ponterio, R De Maria, TL Haas - Frontiers in immunology, 2020 - frontiersin.org
The chimeric antigen receptor (CAR) is an artificial molecule engineered to induce cytolytic
T cell reactions in tumors. Generally, this molecule combines an extracellular single-chain …
T cell reactions in tumors. Generally, this molecule combines an extracellular single-chain …